Clinical Trials
4
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2019
Not yet recruiting
2
50.0%
Recruiting
2
50.0%
No approval data available
- Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802, targeting heme-oncology indications, showcasing their commitment to innovative cancer treatments. - JBI-778, an oral brain-penetrant PRMT5 inhibitor, enters Phase I trials focusing on solid tumors including mEGFR TKI-resistant NSCLC, IDH+ high-grade glioma, and adenoid cystic carcinoma. - JBI-802, a first-in-class dual inhibitor of LSD1 and HDAC6, has demonstrated anti-tumor activity in NSCLC patients, showing promise for treating Essential Thrombocythemia and MDS/MPN. - Initial clinical data from both JBI-802 and JBI-778 trials are anticipated in 2025, marking a significant milestone for Jubilant's precision medicine approach.
- Jubilant Therapeutics has dosed the first patients in global clinical trials for JBI-802, a first-in-class CoREST inhibitor, targeting heme-oncology malignancies. - The company also initiated a Phase I clinical trial for JBI-778, a potential best-in-class, brain-penetrant PRMT5 inhibitor, in patients with solid tumors. - JBI-802 is being evaluated for Essential Thrombocythemia and Myelodysplastic Syndrome/Myeloproliferative Neoplasms, while JBI-778 targets mEGFR TKI-resistant NSCLC, IDH+ high-grade glioma, and Adenoid Cystic Carcinoma. - Initial clinical data from both trials are anticipated in 2025, marking a significant step in Jubilant's mission to develop precision oral medicines.
